Engraftment, GVHD, and infection in CBT and genoidentical BMT
| Parameter . | CB recipient . | BM recipient . |
|---|---|---|
| Median (range) time to neutrophils > 500/μL | 31 d (15-73) | 23 d (13-30) |
| Median (range) time to platelets > 20 000/μL | 87 d (27-398) | 26 d (9-163) |
| Acute GVHD grade, no. (%) | ||
| 0 | 5 (50) | 9 (48) |
| I | 2 (20) | 5 (26) |
| II | 3 (30) | 5 (26) |
| III-IV | 0 (0) | 0 (0) |
| Chronic GVHD grade, no. (%) | ||
| 0 | 6 (60) | 10 (53) |
| Limited | 3 (30) | 8 (42) |
| Extensive | 1 (10) | 1 (5) |
| CMV serology, no. (%) | ||
| Positive recipients | 3 (30) | 13 (68) |
| Positive donors | 0 (0) | 11 (58) |
| Posttransplantation CMV infection, no. (%) | 2 (20) | 5 (26) |
| No. of all serious infections after transplantation (during first y after transplantation) | ||
| 0 | 3 (30) | 10 (53) |
| 1 | 4 (40) | 5 (26) |
| 2 | 1 (10) | 3 (16) |
| 3 | 2 (20) | 1 (5) |
| Parameter . | CB recipient . | BM recipient . |
|---|---|---|
| Median (range) time to neutrophils > 500/μL | 31 d (15-73) | 23 d (13-30) |
| Median (range) time to platelets > 20 000/μL | 87 d (27-398) | 26 d (9-163) |
| Acute GVHD grade, no. (%) | ||
| 0 | 5 (50) | 9 (48) |
| I | 2 (20) | 5 (26) |
| II | 3 (30) | 5 (26) |
| III-IV | 0 (0) | 0 (0) |
| Chronic GVHD grade, no. (%) | ||
| 0 | 6 (60) | 10 (53) |
| Limited | 3 (30) | 8 (42) |
| Extensive | 1 (10) | 1 (5) |
| CMV serology, no. (%) | ||
| Positive recipients | 3 (30) | 13 (68) |
| Positive donors | 0 (0) | 11 (58) |
| Posttransplantation CMV infection, no. (%) | 2 (20) | 5 (26) |
| No. of all serious infections after transplantation (during first y after transplantation) | ||
| 0 | 3 (30) | 10 (53) |
| 1 | 4 (40) | 5 (26) |
| 2 | 1 (10) | 3 (16) |
| 3 | 2 (20) | 1 (5) |